Baicalein Anti-Tumor Effects on Choroidal Melanoma via PI3K/AKT/mTOR Pathway

Integrated analyses and in vitro experiments reveal baicalein's inhibitory effects on choroidal melanoma cell lines. This 27.0 KB Excel file contains results from network pharmacology, transcriptomics, and experimental validation. Lili Wu authored the dataset, which was last updated in April 2026.

Use Cases

• Analyze gene expression changes from transcriptomic data to identify BAI-responsive pathways in C918 and OCM-1 cell lines.
• Validate network pharmacology predictions, such as protein-protein interaction networks, with experimental phosphorylation levels from western blotting.
• Correlate in vitro assay results on cell proliferation and migration with outcomes from the allograft tumor model of C918.
• Investigate the attenuation of BAI's effects by IGF-1 co-treatment data to confirm pathway dependency.

Strengths

• Dataset integrates three methodological approaches: network pharmacology, transcriptomic analysis, and experimental validation.
• Experimental validation includes data from two distinct choroidal melanoma cell lines (C918 and OCM-1) and an in vivo allograft model.

Limitations

• The dataset is very small at 27.0 KB, indicating limited scope and likely a summary of results rather than raw experimental data.
• Specific row counts, column names, and sample-level data are unavailable, restricting detailed re-analysis.

Provenance

Source

Figshare, authored by Lili Wu.

Collection Method

Generated through integrated computational analysis (network pharmacology, molecular docking, transcriptomics) and laboratory experiments (cell assays, western blotting, animal model).

Freshness

Last updated in April 2026.